Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Legend Biotech ( (LEGN) ) has issued an announcement.
On July 16, 2025, Legend Biotech announced that its CARVYKTI® therapy generated approximately $439 million in net trade sales for the quarter ended June 30, 2025. This significant sales figure underscores the product’s market impact, although it remains unaudited and subject to financial statement completion. The announcement reflects Legend Biotech’s strong positioning in the cell therapy market, highlighting the potential for growth and increased stakeholder interest.
The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s strong market momentum and optimistic guidance from the earnings call drive a higher score, despite ongoing profitability challenges and a negative valuation scenario. The promising outlook for CARVYKTI and strategic expansions are key strengths, while cash flow issues and net losses remain significant risks.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of innovative cell therapies. Its primary product, CARVYKTI®, is a chimeric antigen receptor T-cell (CAR-T) therapy aimed at treating multiple myeloma. The company collaborates with Janssen Biotech, Inc. to enhance its market presence.
Average Trading Volume: 1,739,047
Technical Sentiment Signal: Hold
Current Market Cap: $7.26B
For an in-depth examination of LEGN stock, go to TipRanks’ Overview page.